The long-acting antibody combination Evusheld (formerly AZD7442) is approved for use in the US for COVID-19 pre-exposure prophylaxis (prevention).
2022-07-16
Astazeneca antibody therapy approved in the United States for pre-exposure prophylaxis. In a high-risk population,
